Literature DB >> 33876838

Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.

Stefano Cipollari1,2, Neema Jamshidi1,3, Liutao Du3, Kyunghyun Sung3, Danshan Huang3, Daniel J Margolis4, Jiaoti Huang5, Robert E Reiter6, Michael D Kuo1.   

Abstract

BACKGROUND: Tissue clearing technologies have enabled remarkable advancements for in situ characterization of tissues and exploration of the three-dimensional (3D) relationships between cells, however, these studies have predominantly been performed in non-human tissues and correlative assessment with clinical imaging has yet to be explored. We sought to evaluate the feasibility of tissue clearing technologies for 3D imaging of intact human prostate and the mapping of structurally and molecularly preserved pathology data with multi-parametric volumetric MR imaging (mpMRI).
METHODS: Whole-mount prostates were processed with either hydrogel-based CLARITY or solvent-based iDISCO. The samples were stained with a nuclear dye or fluorescently labeled with antibodies against androgen receptor, alpha-methylacyl coenzyme-A racemase, or p63, and then imaged with 3D confocal microscopy. The apparent diffusion coefficient and Ktrans maps were computed from preoperative mpMRI.
RESULTS: Quantitative analysis of cleared normal and tumor prostate tissue volumes displayed differences in 3D tissue architecture, marker-specific cell staining, and cell densities that were significantly correlated with mpMRI measurements in this initial, pilot cohort.
CONCLUSIONS: 3D imaging of human prostate volumes following tissue clearing is a feasible technique for quantitative radiology-pathology correlation analysis with mpMRI and provides an opportunity to explore functional relationships between cellular structures and cross-sectional clinical imaging.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  CLARITY; iDISCO; prostate; prostate cancer; radiogenomics; tissue clearing

Mesh:

Year:  2021        PMID: 33876838      PMCID: PMC9014804          DOI: 10.1002/pros.24129

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.012


  42 in total

Review 1.  The neurobiology of attachment.

Authors:  T R Insel; L J Young
Journal:  Nat Rev Neurosci       Date:  2001-02       Impact factor: 34.870

2.  A history of radiologic pathology correlation at the Armed Forces Institute of Pathology and its evolution into the American Institute for Radiologic Pathology.

Authors:  Mark D Murphey; John E Madewell; William W Olmsted; Pablo R Ros; Harvey L Neiman
Journal:  Radiology       Date:  2011-12-20       Impact factor: 11.105

3.  [PI-RADS classification: structured reporting for MRI of the prostate].

Authors:  M Röthke; D Blondin; H-P Schlemmer; T Franiel
Journal:  Rofo       Date:  2013-02-12

Review 4.  Optical clearing for multiscale biological tissues.

Authors:  Tingting Yu; Yisong Qi; Hui Gong; Qingming Luo; Dan Zhu
Journal:  J Biophotonics       Date:  2017-12-12       Impact factor: 3.207

5.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.

Authors:  J B Welsh; L M Sapinoso; A I Su; S G Kern; J Wang-Rodriguez; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

6.  Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.

Authors:  Ming Zhou; Rajal Shah; Ronglai Shen; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

7.  Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans.

Authors:  Junqian Xu; Peter A Humphrey; Adam S Kibel; Abraham Z Snyder; Vamsidhar R Narra; Joseph J H Ackerman; Sheng-Kwei Song
Journal:  Magn Reson Med       Date:  2009-04       Impact factor: 4.668

8.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.

Authors:  Maximilian Diehn; Christine Nardini; David S Wang; Susan McGovern; Mahesh Jayaraman; Yu Liang; Kenneth Aldape; Soonmee Cha; Michael D Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

9.  The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.

Authors:  Neema Jamshidi; Eric Jonasch; Matthew Zapala; Ronald L Korn; James D Brooks; Borje Ljungberg; Michael D Kuo
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

10.  Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.

Authors:  Eline K Vos; Geert J S Litjens; Thiele Kobus; Thomas Hambrock; Christina A Hulsbergen-van de Kaa; Jelle O Barentsz; Henkjan J Huisman; Tom W J Scheenen
Journal:  Eur Urol       Date:  2013-05-31       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.